Anti-HER2 Antibody-drug Conjugate IBI354

**Semantic type:** Amino Acid, Peptide, or Protein|Pharmacologic Substance

**Definition:** An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) conjugated to a camptothecin derivative, with potential antineoplastic activity. Upon administration of the anti-HER2 ADC IBI354, the anti-HER2 monoclonal antibody targets and binds to HER2 expressed on tumor cells. Upon cellular uptake, the camptothecin derivative inhibits DNA topoisomerase I activity, thereby inhibiting DNA replication and resulting in cell cycle arrest and tumor cell apoptosis. This inhibits the proliferation of HER2-expressing tumor cells. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.

**Synonyms:** - Anti-HER2 ADC IBI354 - IBI 354 - IBI-354 - IBI354